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Inflammation induced by traumatic brain injury (TBI) is a complex mediator of morbidity
and mortality. We have previously demonstrated the utility of both data-driven and
mechanistic models in settings of traumatic injury. We hypothesized that differential
dynamic inflammation programs characterize TBI survivors vs. non-survivors, and sought
to leverage computational modeling to derive novel insights into this life/death bifurcation.
Thirteen inflammatory cytokines and chemokines were determined using LuminexTM
in serial cerebrospinal fluid (CSF) samples from 31 TBI patients over 5 days. In this
cohort, 5 were non-survivors (Glasgow Outcome Scale [GOS] score = 1) and 26 were
survivors (GOS > 1). A Pearson correlation analysis of initial injury (Glasgow Coma Scale
[GCS]) vs. GOS suggested that survivors and non-survivors had distinct clinical response
trajectories to injury. Statistically significant differences in interleukin (IL)-4, IL-5, IL-6,
IL-8, IL-13, and tumor necrosis factor-α (TNF-α) were observed between TBI survivors
vs. non-survivors over 5 days. Principal Component Analysis and Dynamic Bayesian
Network inference suggested differential roles of chemokines, TNF-α, IL-6, and IL-10,
based upon which an ordinary differential equation model of TBI was generated. This
model was calibrated separately to the time course data of TBI survivors vs. non-survivors
as a function of initial GCS. Analysis of parameter values in ensembles of simulations
from these models suggested differences in microglial and damage responses in TBI
survivors vs. non-survivors. These studies suggest the utility of combined data-driven
and mechanistic models in the context of human TBI.
Keywords: inflammation, TBI outcome, mathematical modeling, data-driven modeling, mortality, inflammatory
mediators in CNS
Abbreviations: CBF, cerebral blood flow; CSF, cerebrospinal fluid; DAMP, damage-associated molecular pattern molecule;
GCS, Glasgow Coma Scale; GOS, Glasgow Outcome Scale; IL, interleukin; MIP, macrophage inflammatory protein; TBI,
traumatic brain injury; TNF-α, tumor necrosis factor-α; VEGF, vascular endothelial growth factor.
Abboud et al. Data-Driven and Mechanistic Modeling of TBI
INTRODUCTION
Traumatic brain injury (TBI) remains a leading medical problem
in the United States, causing severe long-term morbidity
and, in some cases, mortality. Between 1.6 and 3.8 million
sports-related concussions alone are reported each year, while
an estimated 5.3 million people are living with long-term
cognitive and psychological impairments annually (Selassie
et al., 2008). These traumatic injuries are caused by direct
and indirect biomechanical forces to the cranium, and result
in a neurometabolic energy crisis in the brain (Giza and
Hovda, 2014). These changes have immediate pathogenic
effects on ion homeostasis, regional cerebral blood flow (CBF),
and cerebral metabolism, while also carrying downstream
“immunoexcitotoxicity” effects by activating immune receptors
on microglia (brain macrophage-like cells) and astrocytes
in response to cellular injury and oxidative stress (Blaylock
and Maroon, 2011; Woodcock and Morganti-Kossmann,
2013). These cellular and molecular cascades can be both
neuroprotective and neurotoxic, and ultimately impact patients’
prognosis and recovery (Selassie et al., 2008).
While the clinical progression and biological underpinnings
of TBI have been studied extensively, accurately predicting a
patient’s prognosis following a TBI remains a difficult challenge
for clinicians. Traditionally, the diagnosis of concussions and
TBI have fallen into a “one size fits all” approach. Recently,
however, there has been impetus toward a multifaceted and
targeted approach that matches a TBI treatment plan with a
number of variable clinical trajectories (Collins et al., 2014). Even
so, current predictors of outcome after severe TBI are neither
sufficiently sensitive nor specific to be used for clinical decision
making in the acute recovery period (Gao and Zheng, 2015).
Thus, although the clinical segregation of TBI patients is
improving, there still remains a need for clear biomarkers and/or
diagnostic modalities to predict individual patient’s likelihood of
recovery, disability, and mortality. This challenge is not unique
to TBI, but has proven to be an obdurate obstacle for health care
providers in the management of many disease states including
cancer, sepsis, and transplantation.
One central process that affects outcomes following TBI
is that of acute inflammation, involving mediators such as
TNF-α, IL-6, IL-8, and IL-10 (Woodcock and Morganti-
Kossmann, 2013). However, the inflammatory response to injury
and infection is complex, dynamic, and highly dependent on
patient-specific conditions. We and others have shown the
efficacy of data-driven computational models in segregating
patients using circulating inflammatory cytokines, chemokines,
and damage-associated molecular pattern (DAMP) molecules
(Zaaqoq et al., 2014; Namas et al., 2015; Almahmoud et al.,
2015a,b; Abboud et al., 2016; Namas et al., 2016b). We have
recently reported on the utility of multiplexed analysis of
circulating inflammatory mediators combined with data-driven
modeling to define potentially novel inflammatory mechanisms
that segregate survivors vs. non-survivors of blunt trauma
(Abboud et al., 2016). Separately, mechanistic mathematical
models have served as the basis for patient-specific predictions
and virtual clinical trials in the setting of human blunt trauma,
including an exploration of the inflammatory characteristics of
survivors and non-survivors (Brown et al., 2015).
Herein, we hypothesized that early TBI-induced inflammation
can foreordain similar patients for survival vs. mortality,
and carried out a combined clinical and in silico study
to gain insights into this process. In the present study,
we sought to gain insights from data-driven modeling to
develop mechanistic models of TBI, in order to better
understand the inflammatory characteristics of TBI survivors and
non-survivors.
MATERIALS AND METHODS
Traumatic Brain Injury Patients
Severe TBI patients were enrolled prospectively as approved by
the University of Pittsburgh Institutional Review Board upon
meeting inclusion criteria judged by the on-call neurosurgeon.
Informed consent was obtained by the legal authorized
representative prior to study procedures. CSF and blood samples
were obtained by trained study personnel for the initial
enrollment and through 5 days of ICU admission. A trained
neuropsychological technician obtained the 6- and 12-month
Glasgow Outcome Scale (GOS) scores. The patient cohort
consisted of 34 TBI patients [29 survivors (27 males/2 females)
and 5 non-survivors (4 males/1 female)]. Non-survivors were
determined by having a Glasgow Outcome Scale (GOS) score of
1 by 12 month follow up, and had a Glasgow Coma Scale (GCS)
score (an estimate of TBI injury severity) of 5.6± 0.58 on hospital
arrival. Survivors had a similar admission GCS of 6.2 ± 0.26
(Table 1), with a GOS score of 2–5.
Clinical Data
The data on each subject consisted of two distinct components,
namely clinical/demographic data and CSF inflammatory
mediator data. Clinical/demographic (one-dimensional)
variables included: age, gender, presence of infection, bleeding,
surgical decompression, presence of subarachnoid hemorrhage,
and initial GCS score. The GCS score quantified the initial brain
injury severity on a numerical scale from 3 to 15. The GOS
score was utilized as the outcome variable and was viewed as the
response variable to study and predict neurological outcome, as
a function of the other input variables. The GOS score quantifies
the neurological outcome at 6 and 12 months post-TBI. GOS
scores ranged from 1 to 5, with 1 indicating death and higher
values indicating a progressively better neurological state of
health.
TABLE 1 | General demographics and injury characteristics of TBI patient
cohort.
Survivors (n = 29) Non-survivors (n = 5)
Age 31.6 ± 5.6 41.0 ± 7.4
Sex ratio (M:F) 27:2 4:1
GCS 6.0 ± 0.24 5.6 ± 0.57
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Inflammatory Mediator Data
In addition to the clinical and demographic data, inflammatory
mediator data were collected from all 34 patients. The data were
plotted as time series for the following 13 cytokines/chemokines
(assayed using LuminexTM multiplexing technology): IL-1α,
IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, macrophage
inflammatory protein (MIP)-1α, MIP-1β, tumor necrosis factor
(TNF)-α, and vascular endothelial growth factor (VEGF). The
inflammatory mediator time series variables varied in both in
length and in the time sequence at which they were collected.
Statistical Analysis
All data were analyzed using SigmaPlotTM 11 software (Systat
Software, Inc., San Jose, CA). Statistical difference between
survivors and non-survivors was determined by Student’s t-
test. Group-time interaction of plasma inflammatory mediators’
levels between survivors and non-survivors was determined by
Two-Way Analysis of Variance (ANOVA) and quantified by
area under the curve (AUC) using the mean values for each
time point, then calculating non-survivors/survivors AUC fold
change. Statistical significance for this study was set at a p < 0.05.
Computational Methods: PCA
Normalized inflammatory mediator data (each measurement
taken to be a single point in 13-dimensional inflammatory
mediator space) were transformed into principal component
space using the MatLab R© function, princomp. We then
examined projections of inflammatory mediators into principal
component space by using the score coefficients for the first 2 or
3 principal components.
Computational Methods: DyBN
We carried out Dynamic Bayesian Network (DyBN) inference
to model the evolution of probabilistic dependencies within a
system over time, and to suggest possible feedback interactions
among inflammatory mediators. This analysis was carried
out using MATLABTM (The Math Works, Inc., Natick, Ma)
as previously described by our group (Azhar et al., 2013;
Almahmoud et al., 2015c; Abboud et al., 2016). Inflammatory
mediators were represented at multiple time points within the
same network structure. The data were separated in adjacent
24 h time periods up to 5 days (0–24 h, 24–48 h...96–120 h).
In this approach, time was modeled discretely as in a discrete
Markov chain. Each mediator was given a time index subscript
indicating the time slice to which it belonged. Additional
temporal dependencies were represented in a DyBN by edges
between time slices. Each node in the network was associated
with a conditional probability distribution of a variable that is
conditioned upon its parents (upstream nodes).
Computational Methods: Ordinary
Differential Equation Model
We constructed a mechanistic model using ordinary differential
equations (ODE), based on core interactions inferred from PCA
and DyBN. Before constructing this model, we sought to gain
further insights into potential relationships between time and
peaks in the CSF levels of these cytokines. Accordingly, the
distributions of Peak time of TNF-α, IL-6, and IL-10) were
plotted. This analysis suggested that most patient’s TNF-α and
IL-10 peak at the early time point (t < 20 h post-injury) and IL-6
peaks slightly later (at∼30 h post-injury).
The model equations are depicted below:
dD
dt
= d0M− d1D
dM
dt
=
(
m0D
1+m1D
+
m2C
1+m3C
+
m4TNF
1+m5TNF
+
m6IL6
1+m7IL6
)
1
1+m8IL10
−m9M
dC
dt
=
c0D
1+ c1D
− c2C
dIL10
dt
= i0M− i1IL10
dTNF
dt
=
t0M
1+ t1IL 10
− t2TNF
dIL6
dt
=
b0M
6
1+ b1IL 10
− b2IL6
Terms in themodel: Damage/dysfunction/DAMPs (D), Activated
inflammatory cells/microglia (M), Chemokine (C), IL-10 (IL10 ),
TNF-α (TNF), IL-6 (IL6 ).
This model encompasses the following biology. Cytokines and
chemokines are produced by inflammatory cells, which in turn
are activated by damage (not directly) and further production
of cytokines and chemokines. Model variables and equations are
the following: damage (D), inflammatory cells (M), chemokine
(C), TNF-α, IL-6, and IL-10. This model incorporates positive
feedback from the pro-inflammatory cytokines TNF-α and IL-
6, and negative feedback from the anti-inflammatory cytokine
IL-10.
The damage variable D is a lumped variable that stands
both for overall tissue damage/dysfunction (e.g., changes in CBF,
elevated intracranial pressure, and associated neurometabolic
changes (Blaylock and Maroon, 2011; Woodcock and Morganti-
Kossmann, 2013; Giza and Hovda, 2014), and, at a molecular
level, the DAMPs released from damaged or dysfunctional
brain tissue (e.g., S100B; Woodcock and Morganti-Kossmann,
2013). This variable is assumed to be driven only by activated
inflammatory cells/microglia (M), and regulated negatively by
both anti-inflammatory influences as well as self-decay. The most
important equation in the model is the one for inflammatory
cells (M), because the level of these cells regulates the level of all
cytokines in this model.
Model parameters and their biological correlates are depicted
in Table 2. Before fitting our models to CSF data from TBI
patients, the actual data including cytokines and GCS (which
represents the initial damage value was normalized to a scale
from 0 to 10. In the case of damage, an initial damage value of
zero is equated with a GCS score of 15, and an initial damage
value of 10 represents a GCS score of 3. For cytokines, the mean
cytokine value in survivors and non-survivors were calculated
at time points: 0, 17, 35, 60, 82, and 104 h. In addition to
the model parameters shown in the equations (see above), two
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additional parameters (the initial values of inflammatory cells
and chemokine) had to be estimated.
Our fitting procedure was as follows. We choose the initial
guess for parameters (randomly or based on previous parameter
estimations) and applied the Nelder-Mead simplex method
for parameter optimization. The error function in our case is
just the sum of errors between computed values of cytokines
from the model equations and the values from original mean
cytokine values (we simply computed the Euclidean distance
between two data vectors). All analysis was performed using
Matlab R©.
RESULTS
TBI Survivors and Non-survivors are Not
Be Segregated by Glasgow Coma Scale
Score, Suggesting Divergent Responses to
Injury
The overall enrollment resulted in a final cohort of 29 survivors
(mean age: 31.6 ± 5.6) with a GCS of 6.0 ± 0.24. Five non-
survivors (mean age: 41.0 ± 7.4, p = 0.172) with a GCS of
TABLE 2 | Parameters of ordinary differential equation model of TBI.
Parameter name Biological function of parameter
d0 Rate of damage/DAMP production by activated inflammatory
cells/microglia
d1 Decay rate of damage/DAMPs
m0 Rate of inflammatory cell activation in response to
damage/DAMPs
m1 Rate of inflammatory cell inhibition in response to
damage/DAMPs
m2 Rate of inflammatory cell activation in response to
chemokines
m3 Rate of inflammatory cell inhibition in response to chemokines
m4 Rate of inflammatory cell production in response to TNF-α
m5 Rate of inflammatory cell Inhibition in response TNF-α
m6 Rate of inflammatory cell activation in response to IL-6
m7 Rate of inflammatory cell inhibition in response to IL-6
m8 Degree to which IL-10 inhibits the activation of inflammatory
cells
m9 Death rate of Inflammatory cells
c0 Rate of chemokine production induced by damage/DAMPs
c1 Degree to which damage/DAMPs inhibit chemokine release
c2 Decay rate of chemokines
i0 Rate of IL-10 production by activated inflammatory cells
i1 Decay rate of IL-10
t0 Rate of TNF-α production by inflammatory cells
t1 Degree to which IL-10 inhibits TNFα
t2 Decay rate of TNF-α
b0 Rate of IL-6 production by inflammatory cells
b1 Degree to which IL-10 inhibits IL-6
b2 Decay rate of IL-6
init_C Initial value for chemokines
Init_M Initial value for inflammatory cells
5.6 ± 0.57, p = 0.313 (Table 1). Thus, there were no significant
differences between groups in age or GCS. A comparison between
groups of initial GCS with a 6 month GOS per patient reveals
no apparent correlation between the severity of the initial head
trauma with 6 month survival (GOS > 1) and mortality (GOS
= 1; Figure 1). These results suggest that patient-specific factors
in response to TBI, rather than magnitude of injury alone, drive
differential outcomes following injury.
We therefore hypothesized that TBI-induced cerebral
inflammation drives, or is associated with, the divergent
outcomes of survival and death following TBI. To test this
hypothesis, we analyzed the dynamics of multiple inflammatory
mediators in the CSF, using both standard statistical analyses and
computational modeling.
Time Courses of CSF Inflammatory
Mediators Segregate Survivors from
Non-survivors
We first hypothesized that dynamics of CSF inflammatory
mediators, as a surrogate for brain inflammation following TBI,
would differ between survivors and non-survivors. In support of
this hypothesis, time course analyses for each of 13 inflammatory
mediators revealed differences in 6 mediators over 5 days by
Two-Way ANOVA, IL-4, 5, 6, 8, 13, and TNF-α (Figures 2A–M).
Notably, levels of IL-6 and IL-8 were the only mediators with
mean values elevated above 1000 pg/ml (Figures 2N,O).
FIGURE 1 | Initial GCS scores could not segregate patients for
mortality vs. survival. An initial GCS score was calculated following the
traumatic insult. The GOS score was utilized as the outcome variable and was
viewed as the response variable. The GOS score quantifies the neurological
outcome at 6 and 12 months post-TBI. GOS scores ranged from 1 to 5, with 1
indicating death and higher values indicating a progressively better
neurological state of health. There were no statistical differences in the mean
GCS between survivors (6.0 ± 0.24) and non-survivors (5.6 ± 0.57, p =
0.313). Furthermore, a plot of GCS vs. GOS was unable to cluster those who
went onto survive (GOS > 1) from those who died (GOS = 1). These findings
highlight the inutility of GCS alone in predicting patient outcomes.
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FIGURE 2 | Time courses of CSF inflammatory mediators segregate survivors from non-survivors. In addition to the clinical and demographic data,
inflammatory mediator data were collected from all 34 patients. The data were plotted as time series for the following 13 cytokines/chemokines. The inflammatory
mediator time series variables varied in both in length and in the time sequence at which they were collected. (A–M) Time course analyses for each of 13 inflammatory
mediators revealed differences in 6 mediators over 5 days by Two-Way ANOVA, IL-4, 5, 6, 8, 13, and TNF-α. The mediator levels were highly variable, oscillating
frequently and at relatively low levels. (N,O) Notably, levels of IL-6 and IL-8 were the only mediators with mean values elevated above 1000 pg/ml.
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Principal Component Analysis Suggests
Conserved General Wiring of Inflammation
in TBI Survivors and Non-survivors
We next sought to gain further insights into how the dynamic
inflammatory responses of TBI survivors and non-survivors
might differ using Principal Component Analysis (PCA), with
the hypothesis that PCA would identify a core inflammation
program, and that principal characteristics/drivers inferred by
PCA would differ between survivors and non-survivors. We
have previously utilized this approach to suggest primary
drivers of inflammation in mice subjected to experimental
trauma/hemorrhagic shock (Mi et al., 2011), in rats undergoing
sepsis in the presence or absence of hemoadsorption as
an experimental treatment (Namas et al., 2012), in swine
undergoing experimental endotoxemia (Nieman et al., 2012),
and in human pediatric acute liver failure (Azhar et al.,
2013) and trauma (Namas et al., 2016a). We first carried out
PCA of the full CSF time course data in all TBI patients,
which identified the first principal component as a linear
combination of TNF-α, MIP-1α, MIP-1β, IL-8, IL-10, and IL-6
(Figure 3A).
This analysis suggested a core, dynamic inflammation
program characterized by chemokines (MIP-1α, MIP-1β,
IL-8), pro-inflammatory cytokines (TNF-α, IL-6), and
anti-inflammatory cytokines (IL-10). This analysis also
supports the well-established roles for IL-6, IL-8, and IL-10
in TBI (Bell et al., 1997; Morganti-Kossman et al., 1997;
Maier et al., 2001; Woodcock and Morganti-Kossmann,
2013).
We next carried out this analysis separately on survivors
and non-survivors, in an attempt to discern whether survival
and death were driven by a differential activation of this core
inflammatory program, due to different initial conditions or
patient-specific characteristics. The separate PCA conducted
on time course CSF data from survivors and non-survivors
suggested similar primary characteristics of inflammation in
these patient sub-groups: IL-6, IL-10, MIP-1β, and IL-8, the first
4 components, were shared by both survivors and non-survivors
(Figures 3B,C).
DyBN Inference Suggests Differential
Activation of the Inflammatory Network in
TBI Survivors and Non-survivors
We next hypothesized that, despite sharing similar primary
characteristics, TBI survivors, and non-survivors would differ
on the basis of dynamic networks of inflammation. Biological
networks often exhibit properties of “switches,” in which inferred
positive and negative feedback structures are hypothesized to
lead to different biological programs depending on the state of
the network (Eungdamrong and Iyengar, 2004; Ferrell, 2013). In
multiple prior studies of the inflammatory response in humans,
we have suggested that “central nodes” in DyBN networks are
those nodes exhibiting self-feedback and also cross feedback with
other self-feedback nodes (Azhar et al., 2013; Zaaqoq et al., 2014;
Almahmoud et al., 2015a,b; Abboud et al., 2016; reviewed in
Namas et al., 2015).
DyBN inference based on time course data from survivors and
non-survivors suggested the presence of a dynamic inflammatory
response encompassing several central nodes connected to
several outputs. Similar to PCA, DyBN inference of data from
both survivors and non-survivors suggested that the cytokine
IL-6 and the chemokine IL-8 were central nodes in the CSF post-
TBI, exhibiting self-feedback and affecting each other as well as
downstream nodes. In addition, DyBN inference in data from
TBI survivors suggested a third mediator, IL-1α, involved in a
hypothetical switch state (Figure 4).
A Mechanistic Model Based on Ordinary
Differential Equations Suggests
Differences in Microglial and Damage
Responses in TBI Survivors vs.
Non-survivors
The foregoing data-driven modeling suggested two key
hypotheses centered on the cytokine IL-6. First, both PCA and
DyBN identified IL-6 as a central characteristic and dynamic
network node, respectively, which is substantiated by multiple
prior studies (Bell et al., 1997; Morganti-Kossman et al., 1997;
Maier et al., 2001; Woodcock and Morganti-Kossmann, 2013).
FIGURE 3 | Survivors and non-survivors share a similar core inflammatory wiring. (A) PCA analysis was carried out on survivor and non-survivor data
combined to assess the underlying inflammatory process. This analysis identified a linear combination of TNF-α, MIP-1α, MIP-1β, IL-8, IL-10, and IL-6 as part of the
first principal component. (B,C) We next carried out this analysis separately on survivors and non-survivors, with the null hypothesis being that there would not be any
significant differences between these groups based on PCA if the core inflammatory “wiring” was overall similar across patients (and if the ultimate life and death
outcome were due to a differential activation of this “wiring” due to different initial conditions or patient-specific characteristics. The first 4 principal components driving
inflammation in survivors and non-survivors were IL-6, IL-10, MIP-1β, and IL-8.
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FIGURE 4 | Non-survivors DyBN was characterized by a bimodal switch state, conferring a homogeneous inflammatory response. Both survivor and
non-survivor inflammatory networks shared the IL-6 and IL- 8 as central nodes, an observation which is supported by elevated levels of both IL-6 and IL-8 in the CSF
analysis. Importantly, a key difference was that the non-survivors system was characterized by a bimodal inflammatory switch state that confers an inevitable and
homogeneous inflammatory response while the survivors had a tri-modal structure. The non-survivors network displayed all outputs shared between IL-6 and IL-8,
irrespective of switch state. Such a network characteristic is congruent with a unimodal inflammatory phenotype, in this case a pathological type which ultimately
leads to mortality. Notably, the survivors system contained the addition of a unique central node, IL-1α, which seemingly conferred a selective advantage for these
patients. Thus, a DyBN inference showing an inflammatory network capable of mounting many diverse responses is a defining feature of survival.
A more specific hypothesis, derived from DyBN inference,
is the presence of positive feedback behavior in IL-6. To test
these hypotheses, and sepcifically the importance of IL-6
positive feedback in driving survival or death, we sought to use
mechanistic mathematical modeling.
We constructed a mechanistic model based on the PCA
and DyBN studies, leveraging prior experience with modeling
acute inflammation mechanistically in the contexts of sepsis,
endotoxemia, traumatic injury, and wound healing (Kumar et al.,
2004, 2008; Chow et al., 2005; Day et al., 2006; Reynolds et al.,
2006; Mi et al., 2007; Daun et al., 2008; Li et al., 2008; Torres
et al., 2009; Nieman et al., 2012; Brown et al., 2015). A key feature
of these prior mechanistic models is the forward feedback loop
of inflammation : tissue damage/dysfunction : inflammation
(An, 2014; Namas et al., 2015), which we hypothesize plays
out in the present context in the form of IL-6 positive
feedback.
To test this hypothesis, we constructed the ODEmodel shown
schematically in Figure 5, in which IL-6 feeds back upon its
own production/release by activated brain microglia (as well
as potentially by astrocytes and neurons) as a function of
damage/DAMPs (such as S100B), whose release is induced by
injury (Woodcock andMorganti-Kossmann, 2013). We included
chemokines in the model as well, based on PCA and DyBN
inference, and due to their role in activating local inflammatory
cells as well as attracting exogenous inflammatory cells into the
brain as the blood-brain barrier breaks down following TBI
(Pearn et al., 2016). Finally, the model included TNF-α and
IL-10 as prototypical pro- and anti-inflammatory mediators,
respectively.
We used ordinary differential equations (ODE) to generate
this fairly abstract, lumped parameter model (see Table 2 for
model parameters); the model building and parameterization
process is detailed in the Section Materials and Methods. We
hypothesized that fitting the TBIODEmodel to data for survivors
separately from non-survivors—and creating ensembles of
survivor-specific and non-survivor-specific models followed by
an interrogation of the changes in parameter values and initial
conditions required to account for these fitted model (Prince
et al., 2006; Namas et al., 2013)—would allow us to gain insights
into how a similar dynamic network of interactions could lead
to such divergent outcomes following TBI. Accordingly, we fit
the ODE model to data as described in the Section Materials
and Methods, leading to an ensemble of simulations depicted
in Figure 6 relative to the CSF levels of TNF-α, IL-6, and IL-
10 in survivors and non-survivors, respectively. In this study,
we ran 100 simulations of which 25 were removed as outliers
relative to the data (leaving 75 simulations total). Overall, both
survivor-specific and non-survivor-specific models fit relatively
well to the IL-10 and TNF-α data, with the fits to IL-6 data being
poorer (Figure 6). The Damage variable fits are plausible given a
GCS score-scaled starting value and a final value scaled to either
survival (damage= 0, the minimal value) or death (damage= 10,
the maximal value).
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FIGURE 5 | Schematic of ODE model. A mechanistic model using ordinary
differential equations (ODE), based on core interactions inferred from PCA and
DyBN and the hypothesis that inflammation drives tissue damage/dysfunction,
release of DAMPs, and further inflammation in a positive feedback cycle
centered on the cytokine IL-6. D, damage/dysfunction/DAMPs; M, activated
inflammatory cells/microglia; C, chemokine.
We next rank-ordered the fold change between survivors’
mean estimated parameter values and ones from non-survivors’
based on 75 simulations, i.e., ratio = SurvivorNon−survivor (see Table 3).
This analysis of ODE model simulations suggested that the key
differences between TBI survivors and non-survivors were as
follows:
• A nearly 6-fold increase in the value of d0, the rate
of damage/DAMP production by activated inflammatory
cells/microglia in response to a given magnitude of injury, in
non-survivors over survivors;
• A nearly 4-fold increase in the value of init_M, the initial
value for inflammatory cells/microglia, in non-survivors over
survivors;
• An approximately 3.5-fold increase in the value of d1,
the decay rate of damage/DAMPs, in survivors over non-
survivors; and
• An approximately 2.7-fold increase in the value of i0, the
rate of IL-10 production by activated inflammatory cells, in
survivors over non-survivors.
Thus, our simulations suggest that key determinants of whether
or not a given TBI patient survives or succumbs to his/her
injuries relate to the baseline levels of activated microglia at the
time of injury, the degree to which microglia produce DAMPs
in response to injury, the degree to which damage is healed or
DAMPs are cleared, and the degree to which microglia produce
IL-10 or other anti-inflammatory mediators.
DISCUSSION
In the present study, we sought to determine if the inflammatory
response induced by injury, assessed in the form of trajectories of
CSF inflammatory mediators analyzed using in silico methods,
would shed insight into why some TBI patients survive and
others die. By collecting serial CSF samples, and generating
data-driven and mechanistic models of inflammation in a small
group of TBI patients, we were able to segregate those who
would survive the traumatic injury from those who would go on
to die.
A central observation of this study was that the GCS alone
could not predict mortality in TBI patients. Patients presenting
with a similar degree of injury were destined for disparate clinical
outcomes. This finding is, of course, not unique to this study, but
has been cited by many and points to the inutility of the GCS as
a tool for predicting patient outcomes (Gao and Zheng, 2015).
Moreover, this finding highlights the difficulty of using clinical
observations and physical examination in the post-TBI setting to
stratify patients for outcomes. This further suggests underlying
causes such as genetic predispositions and aberrant biological
processes—such as differences in the inflammatory response to
brain injury—must be considered in assessing the clinical course
of TBI patients.
Insights from Statistical Analysis and
Data-Driven Modeling
We hypothesized that underlying inflammatory processes
and their downstream immunoexcitotoxic effects would be
imperative to driving pathology following TBI. In support of
this hypothesis, survivors could be differentiated from non-
survivors based on levels of six inflammatory mediators in
the CSF, similar to multiple prior studies (Bell et al., 1997;
Morganti-Kossman et al., 1997; Maier et al., 2001; Woodcock
and Morganti-Kossmann, 2013), albeit with levels that were
dynamically changing in nature and present mostly at low levels.
Thus, the CSF inflammatory mediator analysis highlights the
dynamic complexity of the post-TBI inflammatory response, and
suggests the need for dynamic, non-linear modeling approaches
to capture key features of inflammation in these patients.
One such data-driven approach, DyBN, has been used recently
in the setting of post-traumatic inflammation to successfully
differentiate a group of blunt trauma survivors and non-
survivors (Abboud et al., 2016). In the present study, DyBN
inferred both conserved and divergent dynamic networks in
TBI survivors and non-survivors, respectively. The inferred
dynamic CSF inflammation networks of both survivors and non-
survivors shared the cytokine IL-6 and the chemokine IL-8 as
central nodes, an observation which is supported by significantly
elevated levels of both IL-6 and IL-8 in the CSF in both this
and prior studies (Bell et al., 1997; Morganti-Kossman et al.,
1997; Maier et al., 2001; Woodcock and Morganti-Kossmann,
2013). Importantly, a key difference was that the non-survivors
system was characterized by a bimodal inflammatory switch
state that confers an inevitable and homogeneous inflammatory
response. A key network characteristic was the suggestion that
output nodes are shared between IL-6 and IL-8, irrespective
of which central node (IL-6 or IL-8) dominates the “switch.”
Such a network characteristic is congruent with a unimodal
inflammatory phenotype, in this case a pathological type which
ultimately leads to mortality.
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FIGURE 6 | Comparison of ODE model predictions vs. data. The ODE model described schematically in Figure 5 and detailed in the Section Materials and
Methods was fit separately to the CSF data of TBI survivors and non-survivors, respectively. One-hundred simulations were performed, of which 25 were outliers
relative to the data and so were omitted (resulting in a final total of 75 simulations). The data are shown as box and whisker plots, with black symbols representing
simulated data at the given time point, and the red symbols representing actual data at those time points. Damage variable data are scaled to the GCS and ultimate
survival or death outcome as described in the Section Materials and Methods. (A,E) TNF-α; (B,F) IL-6; (C,G) IL-10; (D,H) Damage.
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TABLE 3 | Fold changes (survivors:non-survivors) in parameter values
from 75 ODE simulations.
Parameter Survivor/non-survivor
d1 3.538564
i0 2.701914
m6 1.235946
m8 1.209746
m7 1.209198
t0 1.163035
m1 1.13622
m5 1.120647
b0 1.111772
c2 1.091208
m9 1.084663
c0 1.071601
init_C 1.045688
b2 0.996189
m3 0.976978
c1 0.958686
b1 0.947126
i1 0.861608
t2 0.86098
m4 0.841159
m2 0.822942
t1 0.759086
m0 0.715864
init_M 0.263824
d0 0.17567
Conversely, the dynamic network inferred in survivors was
characterized by IL-6, IL-8, and an additional central node, IL-
1α, which seemingly conferred a selective advantage for these
patients. In the inflammatory network of survivors, a three-way
switch state with variable output characteristics suggests that
patients who would go on to survive were capable of recruiting
additional inflammatory pathways, through which a survival
advantage was conferred. Thus, we hypothesize that a dynamic
inflammatory network capable of mounting variable responses is
a hallmark of survival. Interestingly, IL-1α is both a cytokine and
a DAMP that is induced in the context of injury (Namas et al.,
2015) that was recently inferred through modeling to be a central
part of the injury response to both peripheral tissues (Starzl et al.,
2015) and nerves (Vasudeva et al., 2015). Furthermore, these
findings may also suggest a host-protective role for IL-1α and
possibly the NLRP3 inflammasome pathway (Davis et al., 2011)
following TBI, which should be studied further.
Insights from Mechanistic Modeling
To expand upon the insights and hypotheses generated from
data-driven modeling, we generated an ODE model that was
based on a core set of interactions discerned from PCA
and DyBN, which in turn were derived from time courses
of CSF inflammatory mediators as a proxy for TBI-induced
inflammation occurring in the injured brain. Thus, the present
study constitutes a progression from data to data-driven
modeling to mechanistic modeling, which we have described as a
rational means by which to progress from data to knowledge (An
et al., 2012). We demonstrated the utility of this general approach
previously, in the context of experimental endotoxemia in swine,
in a study in which we used time course data and PCA to yield
a two-compartment ODE model of acute inflammation (Nieman
et al., 2012). In the present study, this approach was expanded
to include DyBN, in order to go beyond principal characteristics
to a delineation of putative feedback loops and central network
nodes.
The reduced ODE model we generated was on the order of
prior ODE models of acute inflammation (Kumar et al., 2004;
Day et al., 2006; Reynolds et al., 2006). While such reduced
models are often of predominantly theoretical utility rather
than being quantitatively predictive, we nonetheless sought to
parameterize the TBI model with time course of CSF data
from TBI survivors vs. non-survivors. Our goal was to generate
an ensemble of models differing only in the values of model
parameters and initial conditions, but with identical model
structure and similar fit to data, and then to leverage an approach
we have described previously (Prince et al., 2006; Namas et al.,
2013), in which we compared the values of these parameters in
TBI survivors and non-survivors.
Given the relatively abstracted nature of our ODE model,
certain formalisms that are likely not biologically realistic were
employed. A key focus of the model was the inferred positive
feedback behavior of IL-6. In order to obtain reasonable model
fits to the data, we used the sixth power of M in the IL-6
equation to account for this positive feedback behavior because
our experiments with lower powers gave worse fitting results
(data not shown). Though this is likely not biologically plausible,
it is a reasonable formalism given the simplicity of our model and
the fact that the positive feedback behavior of IL-6 likely involves
multiple indirect mechanisms that are not modeled.
Despite such limitations inherent in the process of abstraction,
the ensemble modeling approach we utilized led to several
plausible hypotheses regarding the differences underlying TBI
survivors and non-survivors. These hypotheses center on an
elevated number of activated inflammatory cells/microglia at
baseline in non-survivors vs. survivors; an elevated production of
DAMPs by non-survivor inflammatory cells in response a similar
magnitude of injury; and, conversely, a higher clearance rate for
DAMPs and a higher anti-inflammatory response (assessed as
CSF IL-10) in survivors vs. non-survivors. Future studies are
required in order to both validate these hypotheses and refine
the ODE model to account more explicitly for the biological
interactions abstracted in the current model. Clearly, these
hypotheses are related to the structure of the model we utilized,
which in turn is based on a core hypothesis that our group
has developed over several years regarding the positive feedback
loop of inflammation : damage/dysfunction : inflammation
(An, 2014; Namas et al., 2015). There may well be alternative
hypotheses to explain the evolution of inflammation in TBI,
but this positive feedback-based hypothesis does concur with
the inferred positive feedback behavior of a key inflammatory
mediator, the cytokine IL-6.
This study was primarily limited by the small number of
patients enrolled and the number of data points collected. This
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study could also be improved by utilizing a stringent case-
controlled 1:1 matching protocol to control for confounding
clinical factors between patients. We additionally recognize the
difficulty of obtaining serial CSF samples in a clinical setting,
and suggest further analyses of blood serum and CSF should
be utilized to evaluate the utility of inflammatory mediators
circulating systemically. Lastly, this study was of course limited
in the fact that we could not control for the variability in each
patient’s course of treatment.
CONCLUSIONS
The present study highlights a potential pathway by which
to go from dynamic data via data-driven modeling to
mechanistic modeling in a complex human inflammatory
disease. While further studies are needed in order to
validate key predictions, the present study may point to
both novel mechanistic insights and clinically translational
applications.
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